Research Program for Receptor Biochemistry and Tumor Metabolism, Department of Pediatrics, University Hospital of the Paracelsus Medical University, Salzburg, Austria.
Division of Neuropathology, Department of Pathology and Neuropathology, Neuromed, School of Medicine Campus, Kepler University Hospital, Johannes Kepler University, Linz, Austria.
Front Endocrinol (Lausanne). 2020 Mar 24;11:155. doi: 10.3389/fendo.2020.00155. eCollection 2020.
Expression of neuropeptides and their corresponding receptors has been demonstrated in different cancer types, where they can play a role in tumor cell growth, invasion, and migration. Human galanin (GAL) is a 30-amino-acid regulatory neuropeptide which acts through three G protein-coupled receptors, GAL-R, GAL-R, and GAL-R that differ in their signal transduction pathways. GAL and galanin receptors (GALRs) are expressed by different tumors, and direct involvement of GAL in tumorigenesis has been shown. Despite its strong expression in the central nervous system (CNS), the role of GAL in CNS tumors has not been extensively studied. To date, GAL peptide expression, GAL receptor binding and mRNA expression have been reported in glioma, meningioma, and pituitary adenoma. However, data on the cellular distribution of GALRs are sparse. The aim of the present study was to examine the expression of GAL and GALRs in different brain tumors by immunohistochemistry. Anterior pituitary gland ( = 7), pituitary adenoma ( = 9) and glioma of different WHO grades I-IV ( = 55) were analyzed for the expression of GAL and the three GALRs with antibodies recently extensively validated for specificity. While high focal GAL immunoreactivity was detected in up to 40% of cells in the anterior pituitary gland samples, only one pituitary adenoma showed focal GAL expression, at a low level. In the anterior pituitary, GAL-R and GAL-R protein expression was observed in up to 15% of cells, whereas receptor expression was not detected in pituitary adenoma. In glioma, diffuse and focal GAL staining was noticed in the majority of cases. GAL-R was observed in eight out of nine glioma subtypes. GAL-R immunoreactivity was not detected in glioma and pituitary adenoma, while GAL-R expression was significantly associated to high-grade glioma (WHO grade IV). Most interestingly, expression of GAL and GALRs was observed in tumor-infiltrating immune cells, including neutrophils and glioma-associated macrophages/microglia. The presence of GALRs on tumor-associated immune cells, especially macrophages, indicates that GAL signaling contributes to homeostasis of the tumor microenvironment. Thus, our data indicate that GAL signaling in tumor-supportive myeloid cells could be a novel therapeutic target.
神经肽及其相应受体的表达已在不同类型的癌症中得到证实,它们在肿瘤细胞生长、侵袭和迁移中发挥作用。人甘丙肽(GAL)是一种由 30 个氨基酸组成的调节性神经肽,通过三种 G 蛋白偶联受体(GAL-R、GAL-R 和 GAL-R)发挥作用,这三种受体在信号转导途径上存在差异。GAL 和甘丙肽受体(GALR)在不同的肿瘤中表达,并且已经证明 GAL 直接参与了肿瘤的发生。尽管它在中枢神经系统(CNS)中强烈表达,但 GAL 在 CNS 肿瘤中的作用尚未得到广泛研究。迄今为止,已经在神经胶质瘤、脑膜瘤和垂体腺瘤中报道了 GAL 肽表达、GAL 受体结合和 mRNA 表达。然而,GALR 细胞分布的数据很少。本研究旨在通过免疫组织化学检查不同脑肿瘤中 GAL 和 GALR 的表达。对 7 例前垂体、9 例垂体腺瘤和 55 例不同 WHO 分级的胶质瘤进行了 GAL 和三种 GALR 的表达分析,所用抗体最近已广泛验证其特异性。在前垂体样本中,高达 40%的细胞中检测到高焦点 GAL 免疫反应性,而只有 1 例垂体腺瘤显示低水平的焦点 GAL 表达。在前垂体中,高达 15%的细胞中观察到 GAL-R 和 GAL-R 蛋白表达,而在垂体腺瘤中未检测到受体表达。在神经胶质瘤中,大多数病例中可见弥漫性和局灶性 GAL 染色。在 9 种神经胶质瘤亚型中观察到 8 种 GAL-R。在神经胶质瘤和垂体腺瘤中未检测到 GAL-R 免疫反应性,而 GAL-R 表达与高级别神经胶质瘤(WHO 分级 IV)显著相关。最有趣的是,在肿瘤浸润的免疫细胞中观察到 GAL 和 GALR 的表达,包括中性粒细胞和神经胶质瘤相关的巨噬细胞/小胶质细胞。肿瘤相关免疫细胞,特别是巨噬细胞上存在 GALR,表明 GAL 信号有助于肿瘤微环境的稳态。因此,我们的数据表明,肿瘤支持性髓样细胞中的 GAL 信号可能是一个新的治疗靶点。